NCT05259540View on ClinicalTrials.gov

Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Cervical Cancer
Interventions
DRUG

compound kushen injection combined with pabolizumab

compound kushen injection 20ml/day and pabolizumab 200mg/21 days, both drugs are given intravenously

Trial Locations (1)

310006

Lili Chen, Hangzhou

All Listed Sponsors
lead

Women's Hospital School Of Medicine Zhejiang University

OTHER